Arthropen Vet 250 Injection An aid in the treatment and prevention of non-infectious inflammatory joint disease.

Disease Modifying Osteoarthritis Drug (DMOAD).


Pentosan Polysulfate Sodium 250mg/mL


12 x 6mL Vials per outer carton

50mL Single vial


Arthropen Vet 250 Injection is indicated as an aid in the treatment of non-infectious, inflammatory joint disease in the horse. Clinical applications include the following conditions: osteoarthritis (OA), osteochondritis dissecans (OCD), traumatic joint disease and peri-articular inflammation or where source of the lameness has not been specifically identified.

Arthropen 250 Injection is a Disease Modifying Osteoarthritis Drug (DMOAD). The high concentration of Pentosan Polysulphate in Arthropen Vet 250 has been specifically designed for low volume administration in the horse. It is a sterile solution formulated as an aid in the treatment of non-infectious inflammatory joint disease in horses. Especially useful in treating conditions affecting multiple joints or where the site of lameness cannot be identified.


Pentosan Polysulfate Sodium (PPS) possesses anti-inflammatory, anti-arthritic and chondroprotective activities. It is a semi-synthetic polysaccharide with a linear xylan (pentosan) backbone. Xylan is a hemicellulose derived from plant origin by extraction from the cell walls of hardwoods. The xylan backbone then undergoes sulfation. The degree of sulfation is believed to modulate the potency of the pentosan molecule. Arthropen 250 Injection is fully sulfated.

The beneficial effects of pentosan polysulfate sodium in joint disease are due to the following actions:

• Anti-inflammatory activity.

• Inhibition of neutrophil migration into the joint.

• Inhibition of enzymes implicated in cartilage destruction.

• Stimulation of hyaluronic acid synthesis by synovial fibroblasts, resulting in increased volume and viscosity of synovial fluid.

• Stimulation of proteoglycan synthesis by chondrocytes.

• Fibrinolytic activity, resulting in improved circulation to subchondral bone and peri-articular structures.

• Reduction in Matrix Metalloproteinases (MMP).

• Reduction in bone oedema.


Arthropen is for intramuscular administration only. Anaphylactic reactions resulting in death of the horse have been reported following the intravenous administration of PPS products.

Because of its heparinoid activity, Arthropen is best not used for a period of 40 hours prior to strenuous exercise in horses with a history of Exercise Induced Pulmonary Haemorrhage (EIPH).

An initial course of four injections a week apart is recommended. Horses undergoing heavy training or competition schedules or horses with a chronic lameness problem may benefit from ongoing weekly Arthropen injections.

Contraindicated for use in horses with clotting defects, traumatic haemorrhage, infection, liver/kidney failure, or within 2 days of surgery. Administer by intramuscular injection..


Early treatment is an important step in preventing the products of inflammation from damaging articular cartilage and causing degenerative joint disease.

Dose - 3mg/kg bodyweight (6mL/500kg horse) by intramuscular injection on four occasions with an interval of 5-7 days between injections. Preferable to alternate injection sites from week to week. Best given by deep intramuscular injection. To avoid haemorrhage associated with injection a small needle (eg 21 gauge) is recommended.




If used in performance animals, the regulations of the relevant authorities regarding medication should be observed.


If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131126 or in New Zealand 0800 764 766.


Dispose of empty container by wrapping with paper and putting in garbage. Discarded  needles/sharps should immediately be placed in a designated and appropriately labelled “sharps” container.


Store between 2 and 8°C (Refrigerate. Do not freeze). Protect from light. Store vials in an upright position. Following withdrawal of the first dose, use the remainder of the vial within 28 days or discard the unused portion.


APVMA Approval No. 63265 (Australia)

ACVM No. A10081 (New Zealand)

SENASA No. 12-079 (Argentina)


© Randlab 2019 | All rights reserved